https://www.selleckchem.com/products/YM155.html
Despite delayed bacteremia clearance, targeted antibiotic therapy plus anticoagulation usually provide clinical improvement and a low 30-day mortality rate. BACKGROUND Cryptococcal Meningitis (CM) is estimated to cause 181,000 deaths annually; with the majority occurring in Sub Saharan Africa. Flucytosine is recommended by the World Health Organization as part of the treatment for CM. Widespread use of flucytosine could reduce mortality in hospital by as much as 40% compared to the standard of care, yet due to market failure quality assur
Curtir
Comentario
Compartilhar
